FGF21型
癌症研究
脂肪性肝炎
肝细胞癌
上皮-间质转换
肿瘤坏死因子α
肿瘤微环境
免疫系统
成纤维细胞生长因子
细胞生物学
生物
化学
内科学
内分泌学
医学
免疫学
脂肪肝
癌症
受体
疾病
转移
作者
Xiaoju Shi,Qianqian Zheng,Xingtong Wang,Wei Guo,Ziqi Lin,Yonglin Gao,Emily A. Shore,Robert C.G. Martin,Guoyue Lv,Yan Li
出处
期刊:Science Advances
[American Association for the Advancement of Science (AAAS)]
日期:2024-10-23
卷期号:10 (43)
标识
DOI:10.1126/sciadv.ado9311
摘要
Metabolic dysfunction–associated steatohepatitis is well accepted as a potential precursor of hepatocellular carcinoma. Previously, we reported that fibroblast growth factor 21 (FGF21) revealed a novel anti-inflammatory activity via inhibiting the TLR4–IL-17A signaling, which could be a potential anticarcinogenetic mechanism to prevent to MASH-HCC transition. Here, we set out to determine whether FGF21 has a major impact on Kupffer cells’ (KCs) ability during MASH-HCC transition. We found aberrant hepatic FGF21 and KC pool in human MASH-HCC. Lack of FGF21 up-regulated ALOX15, which converted the oxidized fatty acids to induce excessive KC death and mobilization of monocyte-derived macrophages (MoMFs) for KC replacement. Lack of FGF21 oversupplied free fatty acids for sphingosine-1-phosphate (S1P) cascade synthesis to mediate MASH-HCC transition via S1P-YAP signaling and cross-talk between tumor cells and macrophages. In conclusion, lack of FGF21 accelerated MASH-HCC transition via the S1P-AP signaling. Compromised MoMFs could present as tumor-associated macrophage phenotype rendering tumor immune microenvironment for MASH-HCC transition.
科研通智能强力驱动
Strongly Powered by AbleSci AI